Philogen’s scientific approach features the use of human monoclonal antibody fragments for the targeted delivery of drugs to tissues undergoing angiogenesis (i.e. neoplasias, arthrtitic joints etc...).

To pursue this goal effectively, the angiogenesis-associated antigens to be targeted by antibodies must be accessible, abundant and virtually undetectable in normal vessels.

Philogen has a strong patent position on the generation of specific ligands for the ED-B domain of Fibronectin, the ED-A domain of Fibronectin and certain splice isoforms of Tenascin-C, which are considered the best markers of angiogenesis described to date.

Furthermore in collaboration with the Swiss Federal Institute of Technology in Zurich, Philogen has pioneered a break-through methodology for the discovery of novel vascular markers of pathology using ex-vivo perfusion of tumor bearing rodents or human organs with tumors, immediately after surgical removal. This research effort has led to the patenting of an impressive portfolio of newly discovered tumor-associated antigens, through an original technique involving the ex-vivo biotinylation of vascular proteins followed by proteomic analysis.